Clinical trials
Cardiac Transplant Rejection clinical trials
Below are recruiting cardiac transplant rejection clinical trials, each written for real people, not researchers. We’re tracking 20 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07770659Recruiting
Using MRI to detect early heart transplant rejection
This study tests whether a heart MRI can detect early signs of organ rejection after a heart transplant. If successful, it could reduce the need for frequent biopsies.
Little Rock, ArkansasAges 6–25 - NCT06178744Recruiting
AI in heart transplant ultrasound study
This study uses artificial intelligence to look at echocardiograms (ultrasounds of the heart) from heart transplant patients. It aims to see if AI can help predict rejection or other problems, potentially reducing the need for biopsies.
Rochester, MinnesotaAges 18 years+ - NCT06774365Recruiting
Heart imaging and blood tests for transplant rejection detection
This study uses advanced heart imaging and blood tests to detect a type of rejection that can happen after a heart transplant. It may help doctors diagnose antibody-mediated rejection earlier and more accurately.
Bari, BariAges 18 years+ - NCT07673536Recruiting
Heart transplant monitoring with extracellular vesicles
This study uses tiny particles called extracellular vesicles (which cells release) to check for signs of organ rejection after a heart transplant, aiming for a safer and less invasive alternative to biopsies.
Berlin, State of BerlinAges 18 years+ - NCT05285878Enrolling by invitationPhase 2
Fingolimod to protect kidney function after kidney transplant
This trial tests whether fingolimod can reduce kidney scarring and preserve kidney function after a new kidney transplant. It focuses on people who are in the early period after transplant who may be at risk for scarring in the kidney.
Houston, TexasAges 18–65 - NCT01757730Recruiting
MRI test to measure soft tissue stiffness
This trial uses a special type of MRI to estimate how stiff certain soft tissues are in the body. You may benefit by helping doctors better measure tissue stiffness, which can relate to different health problems.
Columbus, OhioAges 18 years+ - NCT05300451Enrolling by invitationPhase 2
Daratumumab to help lower rejection risk before heart transplant
This Phase 2 trial tests daratumumab to reduce your body’s immune reaction (HLA antibodies) before a heart or heart-and-kidney transplant. It may help lower the risk of immediate, severe rejection in people who already have high antibody levels.
Rochester, MinnesotaAges 18–80 - NCT03707262RecruitingPhase 1/Phase 2
Brother or sister donor transplant using kidney and stem cells
This study tests a combined approach for kidney transplant patients: standard living-donor kidney transplant plus an added “stem cell” component taken from the same sibling donor. It aims to improve transplant outcomes by trying to better control the immune response and reduce complications.
Los Angeles, CaliforniaAges 18 years+ - NCT07046910RecruitingPhase 2
MRI to detect lung rejection after transplant
This study uses a special MRI scan (called hyperpolarized gas MRI) to check for signs of lung rejection after a transplant. The goal is to see if the MRI can help detect rejection earlier and more safely than standard bronchoscopy alone.
Charlottesville, VirginiaAges 18–80 - NCT07412470RecruitingPhase 2/Phase 3
Testing frexalimab vs tacrolimus for new kidney transplant patients
This trial compares a new drug called frexalimab to the standard drug tacrolimus in people who are getting their first kidney transplant. The goal is to see if frexalimab works better and has a safer side effect profile.
Boston, MassachusettsAges 18–70 - NCT06532890Recruiting
Using microRNAs to personalize heart transplant medicines in children
This study is looking at heart transplant children (up to age 18) to see if measuring tiny molecules called microRNAs in the blood can help doctors personalize anti-rejection medicines. It aims to improve how we prevent rejection while reducing side effects.
Aurora, ColoradoAges Up to 18 years - NCT06997471RecruitingPhase 1
Safety of modified stem cell infusion with organ transplant
This early-phase trial tests whether it is safe to give a special type of stem cell transplant (with the naïve T cells removed and only memory T cells left) to people receiving organ transplants. It is for children getting intestine or lung transplants, and for children or adults getting kidney transplants.
Madrid, MadridAges birth+ - NCT05027906RecruitingPhase 1/Phase 2
Study drug AT 1501 for first-time kidney transplant patients
This Phase 1/2 trial tests how safe AT 1501 is and how it works in people getting their first kidney transplant. It aims to improve transplant outcomes by targeting the immune system, while carefully watching for side effects and immune compatibility issues.
Cincinnati, OhioAges 18–100 - NCT06939751Recruiting
Testing microRNA levels to personalize heart transplant care
This trial is studying whether a blood test that measures small molecules called microRNAs can help doctors personalize the medicines used to prevent rejection after a heart transplant. If you qualify, you would help researchers learn how to better match immunosuppression to each patient's needs.
Los Angeles, CaliforniaAges 18–99 - NCT06089486Recruiting
New Heart Scan for Transplant Patients
This study investigates a new heart scan (called a cardiac PET) to detect early signs of blood vessel disease in heart transplant patients. If you had your transplant 2 to 10 years ago, this scan might be an alternative to the usual yearly checkup with an invasive procedure (angiogram).
Calgary, AlbertaAges 18 years+ - NCT04180085RecruitingPhase 2
Belatacept to protect kidneys in heart transplant patients
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
BordeauxAges 18 years+ - NCT06398457RecruitingEarly Phase 1
Darzalex Before Stem Cell Transplant for High-Risk Graft Failure
This trial tests giving a drug called Darzalex Faspro before the usual desensitization and a stem cell transplant for people at high risk of graft failure due to donor-specific antibodies. The goal is to prevent the transplant from failing.
Baltimore, MarylandAges 18 years+ - NCT06751602Enrolling by invitationPhase 2
Belumosudil to prevent kidney scarring after transplant
This trial tests whether a drug called belumosudil can reduce scarring in the kidney after transplant. Scarring can lead to kidney damage over time, and this study aims to stop that from happening.
Houston, TexasAges 18–75 - NCT06325280Recruiting
Exercise MRI for Kids with Heart Conditions
This study uses an MRI while exercising to check heart and lung fitness in children with heart disease. It helps doctors learn more about how to care for kids who have had a heart transplant or were born with heart problems.
Edmonton, AlbertaAges 10–18 - NCT05525507RecruitingPhase 1
Test early immune-tolerance treatment for matched kidney transplant patients
This Phase 1 study tests a treatment plan given after a kidney transplant to help the immune system stay calm and reduce the risk of rejection. Participants must have a well-functioning kidney transplant from a closely matched living donor and meet health and safety requirements.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Cardiac Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cardiac transplant rejection?
- Yes. Clin2 currently lists 20 recruiting cardiac transplant rejection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cardiac transplant rejection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cardiac transplant rejection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.